A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion by Murata, Makoto et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/05/1279/11 $8.00
Volume 197, Number 10, May 19, 2003 1279–1289
http://www.jem.org/cgi/doi/10.1084/jem.20030044
 
1279
 
A Human Minor Histocompatibility Antigen Resulting from 
Differential Expression due to a Gene Deletion
 
Makoto Murata,
 
1, 2 
 
Edus H. Warren,
 
1, 2 
 
and Stanley R. Riddell
 
1, 2
 
1
 
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
 
2
 
Division of Oncology, University of Washington, Seattle, WA 98104
 
Abstract
 
Minor histocompatibility antigens (minor H antigens) are targets of graft-versus-host disease
and graft-versus-leukemia responses after allogeneic human leukocyte antigen identical he-
matopoietic stem cell transplantation. Only a few human minor H antigens have been molecu-
larly characterized and in all cases, amino acid differences between homologous donor and re-
cipient proteins due to nucleotide polymorphisms in the respective genes were responsible for
immunogenicity. Here, we have used cDNA expression cloning to identify a novel human mi-
nor H antigen encoded by 
 
UGT2B17,
 
 an autosomal gene in the multigene 
 
UDP-glycosyltrans-
ferase 2 
 
family that is selectively expressed in liver, intestine, and antigen-presenting cells. In
contrast to previously defined human minor H antigens, UGT2B17 is immunogenic because
of differential expression of the protein in donor and recipient cells as a consequence of a ho-
mozygous gene deletion in the donor. Deletion of individual members of large gene families is
a common form of genetic variation in the population and our results provide the first evidence
that differential protein expression as a consequence of gene deletion is a mechanism for gener-
ating minor H antigens in humans.
Key words: hematopoietic stem cell transplantation • graft-versus-host disease • cytotoxic T 
lymphocyte • UDP glycosyltransferase 2B family • cDNA expression cloning
 
Introduction
 
Allogeneic hematopoietic stem cell transplantation (HSCT)
 
*
 
from a HLA identical donor is curative for a variety of he-
matologic malignancies but GVHD mediated by T cells
transplanted with the stem cell graft remains a major com-
 
plication (1). Minor histocompatibility antigens (minor
H antigens) are the targets of GVHD and consist of HLA
bound peptides, which are derived from cellular proteins
that differ in amino acid sequence between donor and re-
cipient due to polymorphisms in the genome (2). Because
minor H antigens are also targets of the graft-versus-leuke-
mia (GVL) effect, defining the polymorphisms in the ge-
nome that are responsible for generating minor H antigens
and the tissues in which individual determinants are ex-
pressed may lead to novel strategies to reduce GVHD and/
or augment GVL activity after HSCT (3).
The structure, genetics, and tissue distribution have been
characterized for only a few human minor H antigens, al-
though extrapolation from studies in mice suggests a very
large number of minor H antigens are likely to be impor-
tant in human transplantation (4). T cell clones that are spe-
cific for minor H antigens have been derived from alloge-
neic HSCT recipients and provide reagents for discovery of
the genes that encode these antigens using either peptide
elution and mass spectrometry (5), cDNA expression clon-
ing (6), or genetic linkage analysis (7). Human minor H an-
tigens that have been molecularly characterized include
those encoded by the Y chromosome genes 
 
SMCY
 
, 
 
UTY
 
,
 
DFFRY
 
, and 
 
DBY
 
, which are polymorphic with homo-
logues on the X chromosome and are recognized by donor
T cells after sex mismatched HSCT (5, 8–13). Additionally,
four minor H antigens encoded by autosomal genes have
been described and designated HA-1, HA-2, HA-8, and
HB-1 (6, 14–17). The immunogenicity of all of the previ-
ously discovered human minor H antigens results from
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Abbreviations used in this paper:
 
 B-LCL, Epstein Barr virus transformed
lymphoblastoid cells; CYP, cytochrome P450; DC, dendritic cells; GST,
glutathione S-transferase; HSCT, hematopoietic stem cell transplantation;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GVL, graft-ver-
sus-leukemia; minor H antigens, minor histocompatibility antigens; SSP-
PCR, sequence specific primer-PCR; UGT2B17, UDP glycosyltrans-
ferase 2 family, polypeptide B17.T
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polymorphism in the coding sequences of homologous do-
nor and recipient genes that give rise to unique peptides,
which are displayed at the surface of recipient cells bound
to class I MHC and recognized by donor T cells.
Here, we have used cDNA expression cloning to iden-
tify a new autosomal human minor H antigen encoded by
the 
 
UDP glycosyltransferase 2 
 
family, polypeptide
 
 B17
(UGT2B17)
 
 gene. This minor H antigen is presented by
HLA-A
 
*
 
2902 and recognized by CD8
 
 
 
 T cells that were
isolated from a patient with GVHD involving the gas-
trointestinal tract, liver, and skin. In contrast to previously
defined human minor H antigens, the immunogenicity of
UGT2B17 was not due to a polymorphism in the coding
sequence between homologous donor and recipient genes
but resulted from absent expression of 
 
UGT2B17
 
 in donor
cells due to a homozygous deletion of the 
 
UGT2B17
 
 gene.
Analysis of 36 unrelated normal donors demonstrated that
four (11%) were also deficient in 
 
UGT2B17
 
 demonstrating
that this polymorphism is not uncommon in the human
population
 
.
 
 These results provide the first evidence in hu-
mans that minor H antigens can result from discordance in
gene expression as a consequence of homozygous deletion
of individual members of multigene families.
 
Materials and Methods
 
Cell Culture.
 
The CD8
 
 
 
 clone PL8 CTL was isolated from a
blood sample obtained post-transplant from an allogeneic HLA
identical HSCT recipient as described previously (18). HLA typ-
ing was performed by standard serologic methods and revealed
that both the recipient and his sibling donor were HLA-A2,
A29, B44, Cw5, DR3, DR11. PBMCs were obtained from the
transplant recipient after engraftment at the onset of GVHD and
were stimulated in vitro with aliquots of 
 
 
 
-irradiated PBMCs that
had been obtained from the recipient pretransplant and cryopre-
served. After three weekly stimulations, the PL8 CTL clone was
isolated from the polyclonal T cell culture by limiting dilution
cloning. The PL8 CTL clone was propagated by stimulation ev-
ery 14 d with 30 ng/ml of OKT3 monoclonal antibody (Ortho
Biotech), using unrelated allogeneic 
 
 
 
 irradiated (35Gy) PBMCs
and 
 
 
 
 irradiated (50 Gy) Epstein Barr virus transformed lympho-
blastoid cells (B-LCL) as feeder cells. The culture media consisted
of RPMI-HEPES (GIBCO BRL) containing 10% pooled, heat-
inactivated human serum, and IL-2 (50 U/ml; Chiron Corp.).
The T cell clone was used in cytotoxicity and epitope reconstitu-
tion assays either 12–16 d after stimulation (19), or 1 d after thaw-
ing a frozen aliquot. B-LCL were maintained in RPMI-HEPES
with 10% FBS (ATLAS Biologicals). COS cells were obtained
from the American Type Culture Collection and maintained in
DMEM (GIBCO BRL) with 10% FBS.
 
cDNA Library Construction.
 
A cDNA library consisting of
40,000 clones was constructed using the Superscript Choice Sys-
tem (GIBCO BRL). Total RNA was isolated from B-LCL and
poly (A)
 
 
 
 mRNA was prepared by Straight A’s mRNA Isolation
(Novagen). mRNA was converted into cDNA using an oligo-dT
primer that contains a NotI site at its 3
 
 
 
 end and Thermoscript re-
verse transcriptase (GIBCO BRL). The cDNA was ligated to
BstXI adaptors, digested with NotI, size fractionated by column
chromotography, and ligated into BstXI and NotI sites of the
pEAK10 expression vector (EdgeBioSystems). 
 
E. coli
 
 DH10B
(GIBCO BRL) were electroporated with the recombinant plas-
 
mids and transformed clones were selected with ampicillin.
cDNA pools, each comprising 
 
 
 
50 bacterial clones were ampli-
fied in liquid culture for 20 h, following which plasmid DNA
was extracted using the MultiScreen filtration system (Millipore)
and stored in 96-well plates.
 
Transfection of COS Cells and CTL Stimulation Assay.
 
The
cDNA expression cloning methodology for identifying genes
encoding antigens recognized by CD8
 
 
 
 CTL was performed as
described by Boon et al. with modifications (20). In brief, 5 
 
 
 
10
 
3
 
 COS cells were plated in individual wells of 96-well plates,
cultured for 24 h, and then transfected with 80 ng of plasmid
DNA from each pool of the cDNA library and 40 ng of a plas-
mid encoding HLA-A
 
*
 
2902 using the FuGENE transfection re-
agent (Roche). 2 
 
 
 
 10
 
4
 
 CD8
 
 
 
 CTL were added to each well of
COS cells 48 h after transfection, and after a further 24 h of co-
culture at 37
 
 
 
C, IFN-
 
  
 
was measured in the supernatant by
ELISA (Endogen).
 
cDNA Constructs of UGT2B17.
 
Constructs containing either
full-length or a defined portion of the 
 
UGT2B17
 
 gene were gen-
erated from the 4A2 cDNA by PCR and cloned into pEAK10.
Sense and antisense primers contained the recognition sequence
(underlined in the primer sequences) for EcoRV and NotI, re-
spectively, to facilitate cloning of the PCR product into
pEAK10. The following sequences were used: full-length
construct –5
 
 
 
-ATCGGATATCATGTCTCTGAAATGGATG-
TCAGT-3
 
 
 
 (primer A) and 5
 
 
 
-ATCGGCGGCCGCCTAATC-
CCTTTTCTTCTTCTTTCCT-3
 
 
 
; construct I–primer A and
5
 
 
 
-ATCGGCGGCCGCTTAAACGGCATCTGCCAGAAGGA-
3
 
 
 
; construct II–5
 
 
 
-ATCGGATATCATGGTCCTTCTGGCA-
GATGCCGTTAA-3
 
 
 
 (primer B) and 5
 
 
 
-ATCGGCGGCCGC-
TTAGATCATCGACCCCAGAGAAAAC-3
 
 
 
; construct III–primer
B and 5
 
 
 
-ATCGGCGGCCGCTTAGTACAGAAAGGGTAT-
GTTAAGTAGC-3
 
 
 
. An additional construct UGT
 
493–561
 
 was
generated using primer B and 5
 
 
 
-ATCGGCGGCCGCTTACA-
GAAAGGGTATGTTAAGTAGCTC-3
 
 
 
.
 
Transfection of B-LCL with UGT2B17 cDNA.
 
Donor B-LCL
(5 
 
  
 
10
 
6
 
) were electroporated (220 V, 500 
 
 
 
FD) in 200 
 
 
 
l
K-PBS with 15 
 
 
 
g of plasmid DNA encoding the full-length
 
UGT2B17
 
 cDNA and with truncated versions of UGT2B17.
The transfected B-LCL were placed in culture media, selected
with 0.6 
 
 
 
g/ml of puromycin (EdgeBioSystems) beginning 48 h
after transfection, and used as targets in cytotoxicity assays 3 d af-
ter selection.
 
Chromium Release Assay.
 
B-LCL were labeled for 1 h with
 
51
 
Cr, washed twice, dispensed at 2 
 
 
 
 10
 
3
 
 cells/well into tripli-
cate cultures in 96-well plates, and incubated for 4 h at 37
 
 
 
C
with PL8 CTL at various E:T ratios. In peptide recognition as-
says, B-LCL were preincubated with various concentrations of
peptide for 2 h at 37
 
 
 
C before labeling with 
 
51
 
Cr. These cells
were then washed and aliquoted with PL8 CTL as described
above.
 
Peptides.
 
Peptides were synthesized with a free COOH ter-
minus using standard FMOC chemistry. The synthetic peptides
were dissolved in dimethyl sulfoxide and stored at 
 
 
 
20
 
 
 
C.
 
Northern Blot Analysis.
 
Northern blot analysis was performed
by standard methodology. In brief, 20 
 
 
 
g of total RNA was ex-
tracted from B-LCL using RNeasy Minikit (QIAGEN), electro-
phoresed on a 1.2% agarose gel, and transferred to a Nytran Su-
perCharge Membrane (Schleicher & Schuell). The membrane
was hybridized for 2 h at 65
 
 
 
C in ExpressHyb Solution (CLON-
TECH Laboratories, Inc.) with salmon sperm DNA (GIBCO
BRL) and for 16 h at 68
 
 
 
C in the solution with a 
 
32
 
P-labeled
probe from corresponding to nt 400–751 of the 
 
UGT2B17
 
 gene.T
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After washing, the membrane was exposed for 2 d at room tem-
perature on Storage Phosphor Screen (Molecular Dynamics).
A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
probe (CLONTECH Laboratories, Inc.) was used as a control for
RNA integrity and loading. Expression of 
 
UGT2B17
 
 in various
tissues was analyzed using a dot-blot array of poly (A)
 
 
 
 RNA
(MTE; CLONTECH Laboratories, Inc.).
 
Sequence-specific Primer (SSP)-PCR for UGT2B17 in Genomic
DNA and cDNA.
 
The sense and antisense sequence-specific
primers for PCR to detect exon 1 of the 
 
UGT2B17
 
 gene were
(exon 1a) 5
 
 
 
-TGTTGGGAATATTCTGACTATAA-3
 
 
 
 and 5
 
 
 
-
CCCACTTCTTCAGATCATATGC-3
 
 
 
: (exon 1b) 5
 
 
 
-AAA-
TGACAGAAAGAAACAA-3
 
 
 
 and 5
 
 
 
-GCATCTTCACAGAG-
CTTATAT-3
 
 
 
. The sequence specific primers for exon 6 were
5
 
 
 
-GAATTCATCATGATCAACCG-3
 
 
 
 and 5
 
 
 
-ACAGGCAA-
CATTTTGTGATC-3
 
 
 
. The primers for the region 5
 
 
 
 to
 
UGT2B17
 
 were 5
 
 
 
-GGCAGTATCTTGCCAATGT-3
 
 
 
 and 5
 
 
 
-
AGACTCCAAGTGCCAGTT-3
 
 
 
. 38 cycles of amplification
were performed on 0.5 
 
 
 
l genomic DNA prepared from B-LCL
using QIAamp DNA Blood Minikit (QIAGEN), or cDNA syn-
thesized from total RNA using Superscript II (GIBCO BRL).
Each reaction contained 0.4 
 
 
 
l of Advantage 2 Polymerase Mix
(CLONTECH Laboratories, Inc.), 0.2 mmol/L of each of the
four deoxyribonucleotides, 10 pmol of each primer, and PCR
buffer in a volume of 20 
 
 
 
l. Each cycle consisted of denaturation
(94
 
 
 
C; 30 s), annealing (68
 
 
 
C; 20 s), and elongation (72
 
 
 
C; 30 s).
10 
 
 
 
l of the PCR product was analyzed by electrophoresis on a
1.5% agarose gel. The primers for PCR to detect the GAPDH
gene were 5
 
 
 
-TGAAGGTCGGAGTCAACGGATTTGGT-3
 
 
 
and 5
 
 
 
-CATGTGGGCCATGAGGTCCACCAC-3
 
 
 
 and 22 cy-
cles of amplification were used. Expression of 
 
UGT2B17
 
 in vari-
ous tissues was analyzed using a panel of normalized first strand
cDNA prepared from poly (A)  RNA (MTC; CLONTECH
Laboratories, Inc.) as a template for PCR with the sequence spe-
cific primers for exon 1 of UGT2B17 and with the primers for
GAPDH described above.
Generation of Dendritic Cells and B Cells. Immature dendritic
cells (DCs) were generated from cryopreserved PBMC by cultur-
ing for 6 d in AIM-V (GIBCO BRL) with 800 U/ml of recom-
binant human GM-CSF (Immunex) and 500 U/ml of IL-4
(R&D Systems) as described (21). Mature DCs were generated
from immature DCs by culturing for 2 additional days in AIM-V
with recombinant human GM-CSF (800 U/ml), IL-4 (500 U/ml),
IL-6 (1,000 U/ml; R&D Systems), IL-1  (10 ng/ml; R&D
Systems), tumor necrosis factor   (10 ng/ml; R&D Systems), and
prostaglandin E2 (1  g/ml; Sigma-Aldrich) as described previ-
ously (22). Activated B cells were generated by culturing PBMCs
for 15 d on  -irradiated (96 Gy) human CD40L-transfected
NIH3T3 cell (gift from J. Schultze, Dana-Farber Cancer Insti-
tute, Boston, MA) in IMDM (GIBCO BRL) containing IL-4
(100 U/ml) as described previously (23). First strand cDNA was
prepared from total RNA extracted from each subset of APCs us-
ing RNeasy Minikit and reverse transcribed using Superscript II.
PCR to detect UGT2B17 or GAPDH in cDNA was performed
as described above. For other subsets of peripheral blood, a
cDNA panel (Human blood fractions MTC; CLONTECH Lab-
oratories, Inc.) was used as a template for PCR.
Results
Isolation of a cDNA Encoding the Minor H Antigen Recog-
nized by PL8 CTL. The PL8 CTL clone was isolated
from blood obtained from an allogeneic HLA identical
HSCT recipient at the onset of acute GVHD involving the
gastrointestinal tract, liver, and skin. PL8 CTL lysed recipi-
ent B-LCL and 21 of 24 B-LCL lines from unrelated indi-
viduals that shared HLA-A29 with the recipient, but failed
to lyse B-LCL from the donor and 10 unrelated individuals
that shared class I HLA molecules other than HLA-A29
(unpublished data). This data indicated that PL8 CTL rec-
ognizes a minor H antigen that is frequent in the popula-
tion ( 88%) and presented by HLA-A29.
To identify the minor H antigen recognized by PL8
CTL, we constructed a cDNA library from B-LCL that ex-
pressed the antigen and cotransfected COS cells with plas-
mid pools containing  50 cDNAs from the library, and
with a plasmid encoding HLA-A*2902. The transfected
COS cells were cocultured with PL8 CTL and the produc-
tion of IFN-  measured in the supernatant. COS cells
transfected with two of 384 cDNA pools stimulated IFN- 
production (Fig. 1 A). These two positive pools were then
Figure 1. Identification of a cDNA encoding the
minor H antigen recognized by PL8 CTL. (A) Pools of
a cDNA library containing  50 cDNA clones were
transiently transfected into COS cells in individual
wells of a 96-well plate together with a plasmid encod-
ing HLA-A*2902. COS transfectants were cocultured
with PL8 CTL and IFN-  production was measured in
supernatant collected after 24 h. Two pools (indicated
by arrows) stimulated IFN-  production by PL8 CTL.
(B) Isolation of a cDNA that stimulates IFN-  produc-
tion by PL8 CTL. The two pools of cDNA were sub-
cloned in E. coli, and individual plasmids were trans-
fected into COS cells alone or with HLA-A*2902.
Two clones, designated 2H9 and 4A2 stimulated
IFN-  production by PL8 CTL only when trans-
fected with HLA-A*2902. Data is shown as the mean
of triplicate determinations.T
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subcloned, and individual plasmids were rescreened by
COS cell transfection. Two plasmids containing inserts of
2,896 bp and 2,958 bp, respectively, induced HLA-A29–
dependent IFN-  production by PL8 CTL after transfec-
tion into COS cells (Fig. 1 B). The cDNA inserts of each
plasmid were sequenced and a search of DNA sequence da-
tabases revealed that both cDNAs had greater than 99%
identity with the UGT2B17 gene (GI: 4507820).
Identification of the Antigenic Epitope Encoded by
UGT2B17. The UGT2B17 sequence that encoded the
epitope recognized by PL8 CTL was localized by generat-
ing truncated UGT2B17 constructs containing selected
portions of the gene, transfecting each construct into COS
cells with the plasmid encoding HLA-A29, and screening
the COS transfectants for recognition by PL8 CTL. Con-
struct I included nt 52–513 of the primary open reading
frame (ORF) of UGT2B17 and was generated with a TAA
codon at the 3  end to terminate transcription. Constructs
II and III included nt 493–993 and nt 493–564 of
UGT2B17, respectively, and were engineered to have
ATG and TAA codons at the 5  and 3  ends of the primary
ORF, respectively (Fig. 2 A). COS cells transfected with
either construct II or III, but not with construct I, stimu-
lated IFN-  production by PL8 CTL demonstrating that
the antigenic epitope recognized was derived from the 24
amino acid polypeptide encoded by nt 493–564 of
UGT2B17 (Fig. 2 A).
Peptides that bind to HLA-A*2902 frequently contain a
glutamic acid at P2 and tyrosine at the COOH terminus as
preferred anchor residues (24). We examined the amino
acid sequence encoded by nt 493–564 of UGT2B17 for
candidate peptides that might bind to HLA-A*2902 and
identified the 10 mer peptide, AELLNIPFLY, which con-
tained the appropriate anchor residues (Fig. 2 B). Donor
B-LCL were pulsed with various concentrations of synthetic
AELLNIPFLY and tested as targets for PL8 CTL in a cyto-
toxicity assay. PL8 CTL lysed donor B-LCL pulsed with
AELLNIPFLY and half-maximal lysis occurred at peptide
concentrations of 100 fM–1 pM (Fig. 2 C). Synthetic pep-
tides which have 1 amino acid deleted (ELLNIPFLY) or
added (LAELLNIPFLY) to the NH2 terminus, respectively,
also sensitized donor B-LCL for lysis by PL8 CTL, but at a
one to two log higher concentration. We also synthesized
the nonamer peptide AELLNIPFL with the COOH-ter-
minal tyrosine deleted because the computer program PA-
ProC (www.paproc.de) that identifies likely COOH-ter-
minal proteosomal cleavage sites predicted AELLNIPFL,
but not AELLNIPFLY, as a cleavage product of
UGT2B17. Leucine also is a preferred residue at the
COOH terminus for binding to HLA A*2902 (24). The
Figure 2. Identification of the antigenic epitope
encoded by UGT2B17. (A) Location of the epitope-
containing region by transfection of truncated
UGT2B17 constructs. Alignment of 4A2 cDNA
with the UGT2B17 cDNA (NM_001077), the nu-
cleotide numbering of the constructs used for trans-
fection corresponds to that provided for the
UGT2B17 GenBank sequence. Constructs I, II, and
III contained the indicated UGT2B17 sequences
and were transfected with HLA-A*2902 into COS
cells. IFN-  production by PL8 CTL was measured
after coculture with COS transfectants and is indi-
cated by ( ) or ( ) in the right-hand column. (B)
UGT2B17493–564 encodes a decamer peptide with
anchor residues for HLA-A*2902. The amino acid
sequence encoded by UGT2B17493–564 is shown and
a putative epitope for PL8 CTL is boxed. (C) CTL
recognition of donor B-LCL cultured with synthetic
peptides corresponding to UGT2B17 sequences.
The concentration of peptide that elicited half-max-
imal lysis was  0.7 pM for AELLNIPFLY,  6 pM
for ELLNIPFLY,  50 pM for LAELLNIPFLY, and
 80 nM for AELLNIPFL. Specific lysis is shown as
the mean of triplicate cultures at an E:T ratio of 5:1.
(D) Transfection of minigene constructs define a re-
quirement for tyrosine at the COOH terminus of
the naturally processed UGT2B17 epitope. Donor
B-LCL were transfected by electroporation with ei-
ther  UGT2B17493–564 that encodes the 24 amino
acid polypeptide described in B or UGT2B17493–561
that encodes 23 amino acids with the COOH-ter-
minal tyrosine deleted. Transfected B-LCL were se-
lected for 3 d with puromycin (0.6  g/ml). The lysis
of UGT2B17493–564-transfected donor B-LCL (solid
circles), UGT2B17493–561-transfected donor B-LCL
(triangles), recipient B-LCL (squares), and untrans-
fected donor B-LCL (open circles) is shown as the
mean of triplicate cultures at various E:T ratios.T
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synthetic AELLNIPFL sensitized donor B-LCL for recog-
nition by PL8 CTL but at a 5 log higher concentration
than AELLNIPFLY (Fig. 2 C). Therefore, to further define
the COOH terminus of the naturally processed epi-
tope, we transfected donor B-LCL with construct III
(UGT2B17493–564) encoding a 24 amino acid peptide end-
ing with tyrosine at the COOH terminus, or with a con-
struct (UGT2B17493–561) that encoded a 23 amino acid
polypeptide with the COOH-terminal tyrosine deleted,
and analyzed recognition by PL8 CTL. The donor B-LCL
transfected with UGT2B17493–564 were lysed as well as
recipient B-LCL, but donor B-LCL transfected with
UGT2B17493–561 were not recognized at all by PL8 CTL
(Fig. 2 D). These results indicate that the naturally pro-
cessed peptide contains tyrosine and not leucine at the
COOH terminus and suggest the optimal peptide for PL8
CTL is AELLNIPFLY.
The Epitope of UGT2B17 Differs in Amino Acid Sequence
with All Other UGT2B Family Members. UGT2B17 is a
member of the UGT2B multigene family, which presently
consists of 7 genes and 5 pseudogenes and maps to chro-
mosome 4q13. We compared the sequence of the recipient
UGT2B17 cDNA with the canonical sequences of other
UGT2B family members obtained from the GenBank
DNA sequence database (25–31). Although there was a
high degree of homology between UGT2B17 and other
family members, all family members had one or more
amino acid differences in the peptide sequence correspond-
ing to the epitope identified in UGT2B17 (Table I). The
most closely related sequence in this region was that en-
coded by UGT2B15, which contained only a single amino
acid difference, a phenylalanine in place of leucine at P4.
The synthetic peptide (AELFNIPFLY) corresponding to
the UGT2B15 sequence failed to efficiently sensitize donor
B-LCL for recognition by PL8 CTL, although a low level
of lysis was observed at  M concentrations of peptide (Fig.
3). The amino acid sequences of UGT2B10 and UGT2B7
in the epitope region were identical with each other
but differed from UGT2B17 at P4 with a phenylalanine
instead of leucine and at P9 with a valine instead of leucine.
The sequences encoded by UGT2B11,  UGT2B4, and
UGT2B28 also contained the valine substitution at P9 and
either an alanine in place of glutamic acid at P2 (UGT2B11
and  UGT2B28), an arginine in place of proline at P7
(UGT2B11), or a lysine in place of asparagine at P5
(UGT2B4). Synthetic peptides corresponding to the se-
quence of each of these other UGT2B17 family members
also failed to sensitize donor B-LCL for recognition by PL8
CTL (Fig. 3). Taken together, these data identify an im-
portant role for leucine at P4, asparagine at P5, and leucine
at P9 in the UGT2B17 epitope for recognition by PL8
CTL, either directly as T cell receptor contact residues or
as secondary anchor residues for binding, or indirectly by
altering the conformation of T cell receptor contact or
MHC binding residues in the epitope (32).
Immunogenicity of UGT2B17 Is Due to Differential Tran-
scription. All previously defined human minor H antigens
contain amino acid substitutions that result from nucleotide
polymorphism between homologous recipient and donor
genes. We initially presumed that the sequence of the do-
nor and recipient UGT2B17 genes would contain a poly-
morphism in the epitope region. However, a search of the
human genome database of single nucleotide polymor-
phisms failed to uncover any previously described poly-
morphisms in this region of UGT2B17 encoding the
epitope. Therefore, we attempted to isolate UGT2B17
cDNA from donor cells for sequencing to identify a possi-
Table I. Homology between UGT2B17 and Other UGT2B 
Family Members
Members GI numbers Homologya Peptidesb
UGT2B15 475758 97.6 (1555/1593) AELFNIPFLY
UGT2B11 4507822 85.9 (1368/1593) AALLNIRFVY
UGT2B10 4507816 85.2 (1358/1593) AELFNIPFVY
UGT2B7 4507824 85.6 (1363/1593) AELFNIPFVY
UGT2B4 10863940 85.2 (1357/1593) AELLKIPFVY
UGT2B28 16596679 84.2 (1342/1593) AALLNIPFVY
UGT2B29Pc 6979424 82.8 (565/682) Not available
UGT2B27P 6979423 83.9 (559/666) Not available
UGT2B26P 6979422 82.9 (539/650) Not available
UGT2B25P 6979421 82.6 (598/724) Not available
UGT2B24P 6979420 82.3 (596/724) Not available
aHomology between recipient UGT2B17 cDNA and canonical se-
quences of each UGT2B family member is presented as the percentage
and actual number (parentheses) of identical nucleotides.
bAmino acid sequence of the peptides encoded by other family mem-
bers and corresponding to AELLNIPFLY encoded by UGT2B17.
Amino acids that differ from AELLNIPFLY are shown in bold.
cP indicates a pseudogene.
Figure 3. Donor cells pulsed with synthetic peptides corresponding to
homologous sequences of other UGT2B family members are not recog-
nized by PL8 CTL. Donor B-LCL were pulsed with various concentra-
tions of the following synthetic peptides: AELLNIPFLY (encoded by
UGT2B17), AELFNIPFLY (UGT2B15), AALLNIRFVY (UGT2B11),
AELFNIPFVY (UGT2B10 and UGT2B7), AELLKIPFVY (UGT2B4),
or AALLNIPFVY (UGT2B28), and tested as targets for PL8 CTL in a
cytotoxicity assay. Specific lysis is shown as the mean of triplicate cultures
at an E:T ratio of 5:1.T
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ble polymorphic UGT2B17 allele. However, a PCR prod-
uct was not obtained from donor cells despite trying several
primer pairs designed specifically to amplify UGT2B17
(unpublished data). We next determined if the levels of
UGT2B17 gene expression were comparable in total RNA
prepared from recipient and donor cells using a probe that
overlapped the exon 1 sequence encoding the antigenic
peptide and was polymorphic with other UGT family
members to minimize crosshybridization. UGT2B17 tran-
scripts were easily detected in recipient B-LCL and in un-
related HLA-A29  B-LCL that were lysed by PL8 CTL
but not in donor B-LCL or unrelated HLA-A29  B-LCL
that were not lysed by PL8 CTL (Fig. 4, A and B). To de-
termine if lack of recognition by PL8 CTL was solely at-
tributable to the absence of UGT2B17 gene expression, the
full-length UGT2B17 cDNA in a plasmid containing the
puromycin resistance gene was transfected into donor
B-LCL and cells were selected in puromycin. Donor B-LCL
transfected with the UGT2B17 cDNA were lysed equally
well as recipient B-LCL, demonstrating the lack of recog-
nition of donor cells by PL8 CTL resulted entirely from
differential transcription of this gene in recipient versus do-
nor cells (Fig. 4 C).
Lack of Expression of UGT2B17 in Donor Cells Is Due to a
Gene Deletion. Several possibilities could account for the
absence of UGT2B17 transcripts in donor cells, including
a homozygous gene deletion, polymorphism in promoter
sequences, or a polymorphism in the 3  portion of the
gene that resulted in termination of transcription upstream
of the region encoding the epitope and detected by our
probe. To determine if all or a portion of the UGT2B17
gene was deleted in donor cells, we analyzed genomic
DNA prepared from donor B-LCL using SSP-PCR with
primer pairs to detect exon 1 and exon 6 sequences, which
represent the first and last exons of the UGT2B17 gene
(33), and a primer pair that recognizes sequences 5  to the
initiation codon for UGT2B17. PCR products for exon 1,
exon 6, and the region immediately 5  to exon 1 were not
detected by amplification of genomic DNA from donor
B-LCL or minor H antigen–negative B-LCL from unre-
lated individuals but were obtained by amplification of ge-
nomic DNA from recipient B-LCL and unrelated minor
H antigen–positive B-LCL (Fig. 5). These data indicated
that the failure to detect a UGT2B17 transcript in donor
cells was a result of homozygous deletion of a large por-
tion of the UGT2B17 gene including the ATG initiation
codon, exon 1, and at least a portion of exon 6. Analysis of
B-LCL from 36 randomly selected normal individuals by
SSP-PCR identified 4 (11%) that similarly lacked both
exon 1 and exon 6 of UGT2B17 demonstrating that ho-
mozygous deletion of the UGT2B17 gene was not re-
stricted to this particular stem cell donor but occurs as a
variant in the human population.
Expression of UGT2B17 in Tissues and APCs. PL8 CTL
were isolated from an HSCT recipient with GVHD in-
volving the liver, gastrointestinal tract, and skin. To deter-
mine if UGT2B17 was expressed in tissues that were targets
of GVHD in this patient, first-strand cDNA prepared from
different human tissues pooled from multiple donors was
evaluated for sequences corresponding to exon 1 using
SSP-PCR. Expression of UGT2B17 was easily detected in
liver, colon, small intestine, and pancreas, but absent or
barely detectable in other tissues (Fig. 6 A). Similar data
was obtained using hybridization of a dot-blot array of poly
(A)  RNA from human tissues. A dominant signal for
UGT2B17 mRNA was found in liver, colon, and pituitary
gland, with a weaker signal detected in small intestine and
spleen (unpublished data).
The expression profile of UGT2B17 was compatible
with it being a target for T cells mediating GVHD in this
patient. However, studies in murine models have suggested
that expression of minor H antigens by APC is required for
initiating CD8  T cell responses in GVHD (34). Thus, we
investigated the expression of UGT2B17 in subsets of he-
matopoietic cells prepared from cryopreserved pretrans-
plant recipient blood. UGT2B17 was expressed in imma-
ture and mature DC, and resting and activated B cells, but
not in resting or activated T cells (Fig. 6 B). To determine
whether the level of expression was sufficient for mature
Figure 4. UGT2B17 mRNA is transcribed in minor H antigen posi-
tive but not minor H antigen negative cells. (A) Northern blot analysis of
total RNA from recipient and donor B-LCL, and from HLA-A29  B-LCLs
from 4 unrelated donors (designated 1–4). The blot was hybridized with a
32P-labeled UGT2B17 probe for 16 h at 68 C. Detection of GAPDH
mRNA was performed as a control. (B) Cytotoxicity assay for B-LCL by
PL8 CTL. The B-LCL from unrelated donors (1–4) are the same lines
used for analysis of gene expression in Fig. 3 A. Specific lysis is shown as
the mean of triplicate cultures at an E:T ratio of 5:1. (C) Transfection of
UGT2B17 cDNA into donor B-LCL restores recognition by PL8 CTL.
Donor B-LCL were transfected by electroporation with the full-length
construct of UGT2B17, selected for 3 d with puromycin (0.6  g/ml),
and assayed as targets for PL8 CTL. The lysis of UGT2B17-transfected
donor B-LCL (triangles), untransfected donor B-LCL (circles), and recip-
ient B-LCL (squares) is shown at various E:T ratios.T
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1285 Murata et al.
DCs or activated B cells to present the minor H antigen
encoded by UGT2B17 to PL8 CTL, we measured IFN- 
production after coculture of CTL with these APCs. Both
activated B cells and mature DCs stimulated IFN-  pro-
duction by PL8 CTL (Fig. 6 C). These data are consistent
with participation of APC in the induction of T cell re-
sponses to minor H antigens that are expressed by epithelial
cells and serve as targets for GVHD.
Discussion
T cell responses to minor H antigens have been impli-
cated in both GVHD and GVL responses after allogeneic
HLA-identical HSCT, and a more precise understanding of
the genetics and tissue expression of these determinants
could potentially lead to improvements in transplant out-
come. However, the polymorphisms in the genome that
encode minor H antigens and the basis for antigenicity
have been defined for only a few human determinants. In
all cases described so far, human minor H antigens have
been derived from genes that are expressed in both donor
and recipient cells but have polymorphism in their coding
sequences. The resulting changes in amino acid sequence
may alter the processing of recipient and donor peptides
(17), the ability of the peptide to bind MHC (5, 12), or the
ability of T cells to recognize the MHC/peptide complex
(6). Here, we have identified a new human minor H anti-
gen encoded by the UGT2B17 gene and demonstrated that
Figure 5. The UGT2B17 gene is deleted in do-
nor cells and HLA-A*2902 positive cells from unre-
lated individuals that are not recognized by PL8
CTL. (A) UGT2B17 consists of six exons encoded
over 27 Kb of DNA on chromosome 4. Primer
pairs used for PCR to detect exon 1 and exon 6 se-
quences were selected such that at least one primer
of each pair contained nucleotides that were mis-
matched with all other known UGT family mem-
bers. The primer pair for the region immediately 5 
to the UGT2B17 start site was selected to amplify nt
 370 to  30. (B) SSP-PCR for exon 1 and exon 6
sequences of UGT2B17 and PCR for 5  sequences
upstream of UGT2B17 on genomic DNA prepared
from B-LCL. PCR products for exon 1, exon 6 and
the 5  region upstream of UGT2B17 were detected
in the recipient B-LCL and unrelated HLA-A29 
B-LCL that were recognized by PL8 CTL. These
PCR products were sequenced and found to be
identical to UGT2B17 (unpublished data). No
PCR products were detected in donor B-LCL or
unrelated HLA-A29  B-LCL that were not lysed by
PL8 CTL. The B-LCL from unrelated donors (indi-
cated as 1–4) are the same lines used for analysis of
gene expression and cytotoxicity in Fig. 4, A and B.
PCR for GAPDH was performed as a control.
Figure 6. Tissue expression of
UGT2B17. (A) Expression of
UGT2B17 in tissues by RT-PCR.
First-strand cDNA prepared from a se-
ries of different human tissues pooled
from multiple donors was analyzed by
SSP-PCR for UGT2B17 using the exon
1(a) primer pair. The highest level of
expression of UGT2B17 was observed
in cDNA from liver and colon. Detect-
able bands were also obtained from
lung, skeletal muscle, pancreas, spleen, thymus, prostate, testis, ovary, and small intestine.
No band was obtained from heart, brain, placenta, and kidney. PCR for GAPDH was
performed as a control. (B) Expression of UGT2B17 in subsets of PBMC. First-strand
cDNA was isolated from PBMCs or from subsets of PBMCs and analyzed by SSP-PCR
using the exon 1(a) primer pair. A PCR product of the correct size was obtained from
PBMCs, immature and mature DCs, resting and activated CD19  B cells and B-LCL.
No bands were obtained from resting or activated CD4  and CD8  T cells, or from
CD14  cells (monocytes). PCR for GAPDH was performed on all samples as a control.
(C) APCs stimulate IFN-  production by PL8 CTL. PL8 CTL (5   103) were cocul-
tured with B-LCL, mature DCs, and activated B cells (0.625   103) in triplicate wells of
a 96-well plate for 24 h at 37 C. IFN-  production was measured in the supernatant by
ELISA. The mean and SD of triplicate measurements are shown.T
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differential expression in donor and recipient cells as a con-
sequence of a homozygous gene deletion in the donor is
responsible for immunogenicity. This is the first example in
humans of differential expression of a protein as the basis
for generating a minor H antigen. The murine minor H
antigens, H60 and H28, that result in rejection of BALB/B
skin grafts by C57Bl/6 recipients, are also immunogenic as
a result of differential transcription, although the genetic
basis for absent expression of these genes in some strains of
mice remains to be elucidated (4, 35).
The optimal peptide of UGT2B17 for recognition by
PL8 CTL was AELLNIPFLY, which contains preferred
amino acid residues at both of the anchor positions for
binding to HLA-A*2902, and sensitized donor B-LCL for
lysis at pM concentrations. Peptides with one amino acid
deleted or added to the NH2 terminus of AELLNIPFLY,
respectively, or with one amino acid deleted from the
COOH terminus also sensitized donor B-LCL for recogni-
tion by PL8 CTL, although a much higher concentration
of peptide was required. Donor B-LCL that were trans-
fected with UGT2B17493–564 encoding AELLNIPFLY but
not UGT2B17493–561 encoding AELLNIPFL, were recog-
nized by PL8 CTL suggesting tyrosine is the anchor residue
at the COOH terminus of the naturally processed
UGT2B17 epitope presented by HLA-A*2902. The elu-
tion of peptides from HLA-A29 molecules of recipient cells
that reconstitute recognition by PL8 CTL will be required
to conclusively define the NH2 terminus of the naturally
processed peptide, since the synthetic peptides LAELLNIP-
FLY and ELLNIPFLY were both able to sensitize target
cells for recognition by PL8 CTL, albeit at 1–2 log10 higher
concentration than AELLNIPFLY.
The UDP glycosyl transferases are comprised of two
subfamilies, UGT1 and UGT2 (36), and serve a major role
in the conjugation and subsequent elimination of endoge-
nous compounds including steroid hormones and bilirubin,
and potentially toxic exogenous compounds (37). A single
gene located on chromosome 2 encodes several UGT1 iso-
forms that arise by differential splicing of the encoded
mRNA. Mutations of UGT1 family members have been
described and are responsible for the Crigler-Najjar and
Gilbert syndromes (38–40). Individual genes located on
chromosome 4 encode the UGT2 family members, but
clinical syndromes resulting from mutation or deletion of
UGT2 members have not been described. The lack of
UGT2B17 in the adult donor in this study was not clini-
cally significant since this individual had a normal physical
exam, complete blood count, and serum chemistry at the
time of evaluation for donation of hematopoietic stem
cells. UGT2B17 has been shown to catalyze the conjuga-
tion of the 17 -hydroxy position of dihydrotestosterone
(DHT), testosterone, and androstane-3 17 -diol (3 -
Diol), and glucuronidates androsterone (33, 41). Other
UGT family members, such as UGT2B7 and UGT2B15
also conjugate DHT, testosterone, and 3 -Diol, and
UGT2B7 can glucuronidate androsterone (25, 28, 42–44).
Thus, redundancy of other UGT2B family members for
these substrates may compensate for the deficiency of
UGT2B17 in normal individuals and be responsible for the
absence of a clinical phenotype associated with homozy-
gous UGT2B17 deletion.
Despite the redundancy in substrate specificity, there is
significant variation in the nucleotide and amino acid se-
quences of UGT2B17 compared with other UGT2B fam-
ily members. The region of UGT2B17 that encodes the
epitope recognized by PL8 CTL contains one or more
unique amino acids compared with all other family mem-
bers and synthetic peptides corresponding to the sequences
of other family members failed to sensitize donor cells for
recognition by PL8 CTL. We have analyzed other regions
of UGT2B17 that also differ in amino acid sequence with
all other family members using computer algorithms that
identify peptides predicted to bind to class I HLA mole-
cules based on preferred anchor and secondary anchor resi-
dues (45). Several peptides were identified that are pre-
dicted to bind to common HLA alleles such as HLA-A2
and -B44. Thus, studies in donor/recipient pairs that
express these HLA molecules and are discordant for
UGT2B17 gene expression are warranted to determine if
UGT2B17 encodes additional minor H antigens.
Establishing a causative role for individual human minor
H antigens in GVHD after allogeneic HSCT has proven
difficult for several reasons. Until recently, few minor H
antigens were molecularly characterized and reagents and
methods to detect T cells of selected antigen specificities at
tissue sites of GVHD were not available. Additionally,
other factors such as the intensity of the conditioning regi-
men, polymorphism in genes that encode cytokines or cy-
tokine receptors, the intensity of posttransplant im-
munosuppression, and the relative immunodominance of
individual minor H antigens may influence the develop-
ment of clinical GVHD even when disparity for defined
minor H antigens is known to exist (46). Studies in an situ
model of human skin GVHD have demonstrated that T
cells specific for minor H antigens expressed by both epi-
thelial cells and APC induced the histologic features of
GVHD whereas T cells specific for minor H antigens that
are selectively expressed in APC did not cause GVHD (47).
The requirement that the target antigen be expressed in
APC for the induction of GVHD by CD8  CTL is consis-
tent with prior results obtained in vivo in murine models
(34). The patient from whom the PL8 CTL clone was iso-
lated had acute GVHD involving the liver and gastrointes-
tinal tract and we found UGT2B17 was highly and prefer-
entially expressed in both of these target organs. An in situ
model is not available to address the potential for PL8 CTL
to induce GVHD in the liver or intestine, but based on the
known function of UGT2B17, it seemed unlikely this gene
would fulfill the requirement that it be expressed in APCs.
Surprisingly, our data showed that both dendritic cells and
activated B cells express sufficient levels of UGT2B17 to
stimulate PL8 CTL in vitro. While these results are consis-
tent with the principles suggested by murine studies and in
situ models of human GVHD involving the skin, they do
not definitively establish UGT2B17 as a target of GVHD.
However, the development of the SSP-PCR assay used toT
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demonstrate the homozygous deletion of UGT2B17 in the
donor in this study will permit prospective genotyping of
HSCT donors and recipients and analysis of the occurrence
of GVHD in UGT2B17 positive recipients who undergo
HSCT from donors that lack this gene.
The demonstration in this study that differential expres-
sion of proteins in donor and recipient cells provides a
mechanism for generating minor H antigens in humans has
potentially broad implications for understanding T cell re-
sponses that mediate GVHD after allogeneic HSCT. Defi-
ciencies of members of other enzyme families have been
described in humans. These include deletion or lack of
expression of the cytochrome P450 (CYP) family genes
CYP2A6*4,  CYP2D6*5,  CYP2D6*8, and CYP2C19*4,
which metabolize foreign chemicals as well as endogenous
steroids (48–51), and deletion of the glutathione S-transferase
(GST) T1 and GSTM1 genes, which belong to the GST
gene family that detoxify mutagenic hydrophobic and elec-
trophilic compounds (52, 53). Deletions of GSTT1 and
GSTM1 are especially common, occurring in 38 and 50%
of individuals, respectively, and these proteins share only
55% amino acid identity. Both GSTT1 and GSTM1 are
expressed in the gastrointestinal tract and liver and could
potentially be targets of GVHD involving these organs after
HSCT from a donor with a deficiency of one of these en-
zymes into a recipient who expresses the protein (54).
Thus, the novel mechanism responsible for antigenicity of
UGT2B17 may apply to other minor H antigens involved
in allogeneic reactions after HSCT.
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